Systemic adjuvant chemotherapy has played a major role in improving the prognosis
of patients who have breast cancer. Studies have shown that 5-year, disease-free survival
benefit is being achieved with modern chemotherapy regimens. The potential value of
adjuvant systemic therapy for node-negative breast cancer patients has also been confirmed
in the updated overview analysis published by the Early Breast Cancer Trialists' Collaborative
Group [
[1]
]. Overall, recurrence-free survival and overall survival were significantly improved
in the women treated with chemotherapy and tamoxifen [
1
,
2
,
3
,
4
,
5
].To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Laboratory MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomized trials among 28,896 women.N Engl J Med. 1988; 319: 1681-1692
- Current status of Milan adjuvant chemotherapy trials for node-positive and node-negative breast ancer.NCI Monogr. 1986; 1: 45-49
- A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors.N Engl J Med. 1989; 320: 479-484
- A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor negative tumors.N Engl J Med. 1989; 320: 473-478
- Efficiency of adjuvant chemotherapy in high-risk node negative breast cancer. An intergroup study.N Engl J Med. 1989; 320: 485-490
- Treatment of early stage breast cancer.JAMA. 1991; 265: 391-395
- Prognosis and breast cancer—recognition of lethal and favorable prognostic types.Am J Surg Pathol. 1991; 15: 334-349
- Karnofsky memorial lecture. Conceptual and practical advances in the management of breast cancer.J Clin Oncol. 1989; 7: 1380-1397
- The 182 National Survey of Carcinoma of the Breast in the United States by the American College of Surgeons.Surg Gynecol Obstet. 1984; 159: 309-318
- Ten year follow-up results of patients with carcinoma in the breast in a cooperative clinical trial evaluating surgical adjuvant chemotherapy.Surg Gynecol Obstet. 1975; 140: 528-534
- Axillary micrometastases and macrometastasis in carcinoma of the breast.Surg Gynecol Obstet. 1977; 144: 839-842
- The prognostic significance of palpable lymph nodes in cancer of the breast.Cancer. 1969; 23: 243-250
- International (Ludwig) Breast Cancer Study Group. Prognostic importance of occult axillary lymph node micrometastases from breast cancer.Lancet. 1990; 335: 1565-1568
- Axillary node micrometastasis and breast cancer.Lancet. 1991; 337: 1110
- Micrometastasis to axillary lymph nodes from carcinoma of breast. Detection by immunohistochemistry and prognostic significance.Br J Cancer. 1987; 55: 303-306
- The immunocytochemical detection of axillary micrometastasis in breast cancer.Br J Cancer. 1984; 50: 193-197
- Staging and primary treatment.in: Donegan W.L. Spratt J.S. Cancer of the breast. WB Saunders, Philadelphia1988: 336-402
- Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases.Cancer. 1989; 63: 181-187
- Prognostic factors in primary breast cancer.Cancer Surv. 1986; 5: 527-536
- Cancer of the breast: size of neoplasm and prognosis.Cancer. 1969; 24: 1071-1080
- Breast cancer: relationship between the size of the primary tumor and the probability of metstatic dissemination.Br J Cancer. 1984; 49: 709-715
- A long term follow-up study of survival in Stage I (T1N0M0) and Stage II (T1N0M0) breast carcinoma.J Clin Oncol. 1989; 7: 355-366
- Pathological prognostic factors in Stage I (T1N0M0) and Stage II (T1N0M0) breast carcinoma: A study of 644 patients with median follow-up of 18 years.J Clin Oncol. 1989; 7: 1239-1251
- Aspiration cytology of tubular breast carcinoma.Acta Cytol. 1989; 34: 15-20
- Unusual lesions and their management.Surg Clin North Am. 1990; 70: 963-975
- Cytological grading of breast carcinoma: a feasible proposition?.Cytopathology. 1990; 1: 287-295
Howart AJ, Armstrong GR, Briggs WA, et al. Fine needle aspiration of palpable breast lumps: a 1-year audit using the cytospin method. Cytopathology 1992;3:17–22.
- Duct carcinoma of breast: nuclear grade as predictor of S-phase fraction.Hum Pathol. 1993; 24: 652-656
- Prognostic value of cytological grading of fine needle aspirates from breast carcinomas.Lancet. 1994; 343: 947-949
- Histologic grading of breast cancer.Pathol Annu. 1980; 15: 239-251
- Prognostic value of nuclear grading in breast cytology.Mod Pathol. 1994; 10: 263-267
- Applicatoin of the Scarff-Bloom-Richardson tumor grading system to fine needle aspirates of the breast.Am J Clin Pathol. 1994; 101: 262-265
- Prognostic factors from the fine needle aspirate: breast carcinoma nuclear grade.Diagn Cytopathol. 1994; 10: 203-208
- Cytologic nuclear grading of fine needle aspirates of the breast carcinomas: concordance with histopathologic and flow data.Mod Pathol. 1990; 2: 14A
- Value of cytoprognostic classification in breast carcinomas.J Clin Pathol. 1986; 39: 489-496
- The influence of the wet-fixed Papanicolaou and air-dried Giemsa techniques on nuclear parameters in breast cancer cytology: a cytomorphometric study.Diagn Cytopathol. 1987; 3: 256-261
- Fine-needle aspiration cytology of metastatic neoplasms in the breast.Am J Clin Pathol. 1989; 92: 27-35
- Prognostic value of breast cancer cytologic grading: a retrospective study of 213 cases.Diagn Cytopathol. 1993; 9: 160-163
- Breast cancer.N Engl J Med. 1992; 327: 390-392
- Management of Stage II primary cancer with primary chemotherapy, surgery and radiation therapy.Cancer. 1988; 62: 2507-2516
- On treatment of inoperable cases of carcinoma of the mamma. Suggestions for new method of treatment with illustrated cases.Lancet. 1986; 2: 104
- Studies on prostatic cancer. The effect of castration of estrogen and androgen injection on serum phosphatase in metastatic carcinoma of the prostate.Cancer Res. 1941; 168: 9-12
- Inhibition of human mammary and prostatic cancers by adrenalectomy.Cancer Res. 1952; 12: 134-141
- Hyphophysectomy in management of metastatic carcinoma of breast.in: Currie A. Endocrine aspects of breast cancer. Proceedings of conference held at University of Glasgow. Churchill Livingstone, Edinburgh1958: 27-35
- Bilateral adrenalectomy in metastatic mammary cancer: an analysis of sixty-four cases.Cancer. 1969; 23: 145-151
- Studies with tritium labelled hexestrol in advanced breast cancer.Lancet. 1961; 2: 796-798
- A receptor molecule for estrogens: isolation from the rat uterus and preliminary characterization.Proc Natl Acad Sci USA. 1966; 55: 1574-1581
- Pattern of hormone receptor interactions.in: Griffiths K. Pier-Repoint E.G. Some aspects of aetiology and biochemistry of prostatic cancer. Alpha Omega Alpha 151, Cardiff (UK)1970
- Estrogen receptors in human breast cancer tissue.Am J Obstet Gynecol. 1972; 113: 337-382
- Oestrogen receptors in human breast cancer tissue and response to endocrine therapy.BMJ. 1973; 2: 750-752
- Predictability of response to endocrine ablation in advanced breast carcinoma.Arch Surg. 1973; 106: 515-519
- Correlation between certain biochemical properties of breast cancer and response to therapy. Preliminary report.Cancer. 1974; 33: 303-339
- Predicting a response to endocrine therapy in human breast cancer. A hypothesis.Science. 1975; 189: 726-727
- Progesterone receptors as a prognostic factor in Stage II breast cancer.N Engl J Med. 1983; 309: 1343-1347
- Estrogen and progesterone receptors in cytology.Diagn Cytopathol. 1992; 8: 475-491
- Potential value of estrogen receptor immunocyto-chemical assay in formalin fixed breast tumors.Mod Pathol. 1990; 3: 6,724-6,728
- The value of estrogen and progesterone receptors in the treatment of breast cancer.Cancer. 1980; 46: 2884-2888
- Correlation of primary breast cancer histopathology and estrogen receptor content.Breast Cancer Res Treat. 1981; 1: 37-41
- DNA flow cytometry and prognostic factors in 1331 frozen breast cancer specimens.Cancer. 1988; 61: 420-427
- Receptors.in: Harris J.R. Hellman S. Henderson I.C. Breast diseases. JB Lippincott Company, Phildelphia1987: 210
- Mitosis counting in tumors.Hum Pathol. 1990; 21: 683-685
- The morphometric prognostic index is the strongest prognosticator in premenopausal lymph node negative and lymph node positive breast cancer patients.Hum Pathol. 1990; 22: 326-330
- Pathologic correlates of survival in 378 lymph node negative infiltrating ductal breast carcinomas. Mitotic count is the best single predictor.Cancer. 1991; 68: 1309-1317
- Predicition of early course of breast carcinoma by thymidine labelling.Cancer. 1983; 51: 1879-1886
- The long term prognostic significance of the thymidine labeling index in breast cancer.Int J Cancer. 1984; 33: 441-445
- Practical breast carcinoma cell kinetics: review and update.Breast Cancer Res Treat. 1984; 4: 79-88
- Tumour DNA ploidy as an independent prognostic factor in breast cancer.Br J Cancer. 1987; 56: 637-642
- Improving the prognostic value of DNA flow cytometry in breast cancer by combining DNA index and S-phase fraction. A proposed classification of DNA histograms in breast cancer.Cancer. 1988; 62: 2183-2190
- Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry.N Engl J Med. 1989; 320: 627-633
- Prognostic significance of flow cytometric DNA analysis in node-negative breast cancer patients.Cancer. 1990; 65: 2315-2320
- Is DNA ploidy an independent prognostic indicator in infiltrative node-negative breast adenocarcinoma?.Cancer. 1990; 65: 1577-1582
- The prognostic significance of nuclear DNA in invasive breast cancer—a study with long-term follow-up.Br J Cancer. 1989; 60: 693-700
- Indicators of prognosis in node-negative breast cancer.N Engl J Med. 1990; 322: 1045-1053
- DNA flow cytometric analysis of primary operable breast cancer. Relation of ploidy and S-phase fraction to outcome of patients in NSABP B-04.Cancer. 1991; 68: 1465-1475
- Prognostic factors in node-negative breast cancer.Arch Surg. 1992; 127: 1386-1390
- Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast.Cytometry. 1993; 14: 482-485
- Association of DNA index and S-phase fraction with prognosis of nodes positive early breast cancer.Cancer Res. 1987; 47: 4729-4735
Stal O, Sullivan S, Wingren S, Carstensen J, et al. C-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. Eur J Cancer 1995;31A(13–14):2185–90.
- The relation of flow cytometry to clinical and biologic characteristics in women with node negative primary breast cancer.Cancer. 1989; 64: 1894-1900
- Flow cytometry in primary breast cancer: improving the prognostic value of the fraction of cells in the S-phase by optimal categorisation of cut-off levels.Br J Cancer. 1990; 62: 786-790
- DNA index, S-phase fraction, histological grade and prognosis in breast cancer.Br J Cancer. 1990; 61: 672-674
- Predictive value of nuclear DNA content in breast cancer in relation to clinical and morphological factors. A retrospective study of 227 consecutive cases.Cancer. 1988; 62: 521-530
- Response to Beerman et al, “Flow cytometric analysis of DNA stemline heterogeneity in primary and metastatic breast cancer.”.Cytometry. 1991; 12: 155-156
- Guides to clinical aspiration biopsy: flow cytometry.Igaku-Shoin, New York1991
- Use of fine needle aspiration biopsy specimens in DNA flow cytometry study.Am J Clin Pathol. 1989; 92 (535(A))
- Modalities of synthesis of Ki-67 antigen during the stimulation of lymphocytes.Cytometry. 1989; 10: 731-738
- Flow cytometric analysis of proliferation associated nuclear antigen using washless staining of unfixed cells.Cytometry. 1992; 13: 230-240
- Detection of growth fraction in tumors by Ki-67 monoclonal antibody in cytologic smears: a prospective study of 40 cases.Diagn Cytopathol. 1993; 9: 52-56
- Cytologic assessment of tumor cell kinetics. Applications of monoclonal antibody Ki-67 to fine needle aspiration smears.Diagn Cytopathol. 1991; 7: 591-596
- Prognostic factors in breast cancer, use of fine needle aspirates.Acta Cytol. 1992; 36: S84-S96
- Proto-oncogene abnormalities in human breast cancer: correlations with anatomic features and clinical course of disease.J Clin Oncol. 1987; 5: 999-1000
- Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.Science. 1987; 235: 177-182
- HER-2/neu oncogene protein and prognosis in breast cancer.J Clin Oncol. 1989; 7: 1120-1128
- Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic signficance of erbB-2 protein overexpression in primary breast cancer.J Clin Oncol. 1990; 8: 103-112
- HER-2/neu in node negative breast cancer. Prognostic significance of overexpression influenced by presence of in situ carcinoma.J Clin Oncol. 1992; 10: 599-605
- HER-2/neu oncogene expression in atypical hyperplasia, carcinoma in situ and invasive breast cancer.Mod Pathol. 1991; 4: 12A
- HER-2/neu gene amplification in breast imprint cytology analyzed by fluorescence in situ hybridization: direct comparison with companion tissue sections.Diagn Cytopathol. 2000; 23: 299-302
- Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomoas. Correlation with oncogene amplification in 160 cases.Am J Clin Pathol. 2000; 113: 675-682
- erbB2/neu gene and chromosome 17 analysis in breast cancer by FISH on archival cytological fine-needle aspirates.Br J Cancer. 1999; 80: 519-525
- Assessment of HER-2/neu overexpression in primary breast cancers and their metastatic lesions: an immunohistochemical study.Ann Clin Lab Sci. 2000; 30: 259-265
- Fluorescence in situ hybridization detection of erbB2 amplification in breast cancer fine needle aspirates.Mol Pathol. 1999; 52: 75-77
- The p53 proto-oncogenes can act as a suppressor of transformation.Cell. 1989; 57: 1083-1093
- Molecular themes in oncogenes.Cell. 1991; 64: 235-248
- Mutations in p53 gene in primary human breast cancers.Cancer Res. 1991; 51: 6194-6198
- Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancer.J Natl Cancer Inst. 1992; 84: 845-855
- Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients.J Natl Cancer Inst. 1992; 84: 1109-1114
- Increased accumulation of the p53 suppressor gene product is an independent prognostic variable for breast cancer.J Natl Cancer Inst. 1992; 84: 845-855
Addonizio LJ, Robbins RC. Pulmonary vascular resistance. In: Smith JK, editor. Proceedings of the Fourth International Symposium on Circulation. Las Vegas (NV): Real Science Press; 1987. p. 12–189.
- p53 oncosuppressor protein in carcinoma of the breast.Mod Pathol. 1991; 6 (80(a))
- Relation between p53 overexpression and established prognostic factors in breast cancer.Surgery. 1991; 110: 259-264
- p53 mutations and overexpression in locally advanced breast cancer.Br J Cancer. 1994; 69: 1145-1150
- Maintenance of p53 alterations throughout breast cancer progression.Cancer Res. 1991; 51: 2605-2610
Article info
Identification
Copyright
© 2005 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
